课题基金 / 基金详情

Strategies for Evaluating and Treating Early Synovitis

Strategies for Evaluating and Treating Early Synovitis
评估和治疗早期滑膜炎的策略
批准号:
6804733
负责人:
DAVID STEPHEN PISETSKY
金额:
$7.7万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-25 至 2006-06-30

项目摘要

项目成果

DAVID STEPHEN PISETSKY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goal of this application for a High Risk Rheumatic and Musculoskeletal and Skin Diseases Research grant is to develop a strategy for studying early synovitis and provide a framework to test the window-of-opportunity hypothesis in the treatment of rheumatoid arthritis (RA). RA is a chronic inflammatory arthritis that can lead to deformity and disability. Among drugs to treat RA, DMARDs (disease modifying anti-rheumatic drugs) can improve the signs and symptoms of arthritis and prevent or slow the destruction of cartilage and bone that leads to deformity. Since early treatment with DMARDs improves clinical outcomes, there is a strong rationale for instituting these agents early in the course of disease. Such early use, however, is complicated by diagnostic uncertainty, including the difficulties in differentiating patients with RA from those with inflammatory arthropathies other than RA as well as the occurrence of remission in early disease. Furthermore, efforts to institute therapy early may be limited by delays in patients seeking care as welt as provider uncertainty or reluctance to begin DMARDs early. Resolution of these issues can be best accomplished in the context of a comprehensive program of clinical research that will ultimately include a clinical trial to assess the window-of-opportunity hypothesis. This hypothesis states that the aggressive treatment of synovitis early in disease may prevent the emergence of RA or other persistent synovitis. At present, there is national and international interest in the conduct of such a trial and the opportunities it provides for addressing critical issues in disease pathogenesis. This high-risk grant will therefore address fundamental questions in the recruitment and identification of patients with early disease and establish the basis for a clinical trial. Three specific aims are proposed: 1) to develop a clinical trial to test the window-of-opportunity hypothesis; 2) to test recruitment of patients in a pilot study; and 3) to assess ethical issues of early intervention.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Early rheumatoid arthritis.
早期类风湿性关节炎。
DOI: 10.1097/bor.0b013e32805e87bf
发表时间: 2007
期刊: Current opinion in rheumatology
影响因子: 5.1
作者: [Mitchell,KateL, Pisetsky,DavidS]
通讯作者: Pisetsky,DavidS
DOI: 10.1186/s13075-018-1667-z
发表时间: 2018-08-09
期刊: Arthritis research & therapy
影响因子: 4.9
作者: [Stamm TA, Machold KP, Aletaha D, Alasti F, Lipsky P, Pisetsky D, Landewe R, van der Heijde D, Sepriano A, Aringer M, Boumpas D, Burmester G, Cutolo M, Ebner W, Graninger W, Huizinga T, Schett G, Schulze-Koops H, Tak PP, Martin-Mola E, Breedveld F, Smolen J]
通讯作者: Smolen J
Cellular Sources of Self Antigen in SLE
  • 批准号:
    10265341
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2018
  • 负责人:
    DAVID STEPHEN PISETSKY
  • 依托单位:
MECHANISMS OF AUTOIMMUNITY IN SLE
  • 批准号:
    8044328
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2011
  • 负责人:
    DAVID STEPHEN PISETSKY
  • 依托单位:
MECHANISMS OF AUTOIMMUNITY IN SLE
  • 批准号:
    8198380
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2011
  • 负责人:
    DAVID STEPHEN PISETSKY
  • 依托单位:
MECHANISMS OF AUTOIMMUNITY IN SLE
  • 批准号:
    8398955
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2011
  • 负责人:
    DAVID STEPHEN PISETSKY
  • 依托单位:
海外基金